{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:03:24Z","timestamp":1793109804143,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Vaccines Europe"},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40266-026-01284-y","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:09:04Z","timestamp":1772820544000},"page":"223-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancing Vaccination Strategies for Older Adults: Insights of the Adult Immunization Board Meeting"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-0297","authenticated-orcid":false,"given":"Marco","family":"Del Riccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wieczorowska-Tobis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Botelho-Nevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Barrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litjen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boccalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bechini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Pattyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1284_CR1","unstructured":"European Commission. The impact of demographic change in Europe 2024. https:\/\/commission.europa.eu\/strategy-and-policy\/priorities-2019-2024\/new-push-european-democracy\/impact-demographic-change-europe_en?utm_source=chatgpt.com. Last Accessed 30 Oct 2025."},{"issue":"Suppl 1","key":"1284_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40121-024-01079-x","volume":"14","author":"R Debbag","year":"2025","unstructured":"Debbag R, Rudin D, Ceddia F, Watkins J. The impact of vaccination on COVID-19, influenza, and respiratory syncytial virus-related outcomes: a narrative review. Infect Dis Ther. 2025;14(Suppl 1):63\u201397.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"1284_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QCO.0000000000001000","volume":"37","author":"S Kenmoe","year":"2024","unstructured":"Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis. 2024;37(2):129\u201336.","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"1284_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1086\/515205","volume":"28","author":"K Schmader","year":"1999","unstructured":"Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis. 1999;28(4):736\u20139.","journal-title":"Clin Infect Dis"},{"key":"1284_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83\u201394.","journal-title":"Semin Immunol"},{"key":"1284_CR6","unstructured":"United Nations. United Nations Decade of Healthy Ageing (2021\u20132030): resolution\/adopted by the General Assembly on 14 December 2020. Resolution A\/75\/L.47. UN 21 December 2020."},{"key":"1284_CR7","unstructured":"World Health Organization. Healthy ageing and functional ability 2020. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/healthy-ageing-and-functional-ability. Last Accessed 30 Oct 2025."},{"issue":"10033","key":"1284_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","volume":"387","author":"JR Beard","year":"2016","unstructured":"Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel JP, et al. The World Report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145\u201354.","journal-title":"Lancet"},{"key":"1284_CR9","unstructured":"WHO European Region. Lisbon Outcome Statement: regional summit on policy innovation for healthy ageing in the WHO European Region. 2023. https:\/\/www.who.int\/europe\/publications\/i\/item\/lisbon-outcome-statement--regional-summit-on-policy-innovation-for-healthy-ageing-in-the-who-european-region--10-11-october-2023-lisbon--portugal. Accessed 30 Oct 2025."},{"issue":"5","key":"1284_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","volume":"145","author":"CE Gustafson","year":"2020","unstructured":"Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145(5):1309\u201321.","journal-title":"J Allergy Clin Immunol"},{"key":"1284_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579972","volume":"11","author":"MA Batista","year":"2020","unstructured":"Batista MA, Calvo-Fortes F, Silveira-Nunes G, Camatta GC, Speziali E, Turroni S, et al. Inflammaging in endemic areas for infectious diseases. Front Immunol. 2020;11:579972.","journal-title":"Front Immunol"},{"key":"1284_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2017","unstructured":"Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960.","journal-title":"Front Immunol"},{"issue":"10","key":"1284_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.","journal-title":"Genome Biol"},{"issue":"12","key":"1284_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.18632\/aging.100861","volume":"7","author":"S Horvath","year":"2015","unstructured":"Horvath S, Pirazzini C, Bacalini MG, Gentilini D, Di Blasio AM, Delledonne M, et al. Decreased epigenetic age of PBMCs from Italian semi-supercentenarians and their offspring. Aging (Albany NY). 2015;7(12):1159\u201370.","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"1284_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/gerona\/glt190","volume":"69","author":"J Kri\u0161ti\u0107","year":"2013","unstructured":"Kri\u0161ti\u0107 J, Vu\u010dkovi\u0107 F, Menni C, Klari\u0107 L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol: Ser A. 2013;69(7):779\u201389.","journal-title":"J Gerontol: Ser A"},{"key":"1284_CR16","doi-asserted-by":"crossref","unstructured":"Cevirgel A, van der Heiden M, Shetty SA, Viljanen M, Vos M, Bijvank E, et al. Baseline immunotypes and immune entropy are indicators of multiple vaccine responsiveness. medRxiv. 2024:2024.05.29.24308098.","DOI":"10.1101\/2024.05.29.24308098"},{"key":"1284_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040401","author":"A Vilajeliu","year":"2025","unstructured":"Vilajeliu A, Vega V, Gibson R, Nogareda F, Wang X, Brooks DJ, et al. Global status of adult immunization post COVID-19 pandemic. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13040401.","journal-title":"Vaccines"},{"key":"1284_CR18","unstructured":"European Centre for Disease Prevention and Control. Survey report on national seasonal influenza vaccination recommendations and coverage rates in EU\/EEA countries. Stockholm: ECDC; 2024."},{"issue":"1","key":"1284_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14760584.2025.2550986","volume":"24","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang Y, Wang J, Shi N, Jin H, Jin H. Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies. Expert Rev Vaccines. 2025;24(1):17\u201327.","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"1284_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1586\/14760584.6.5.699","volume":"6","author":"DT O'Hagan","year":"2007","unstructured":"O\u2019Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6(5):699\u2013710.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"1284_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13286","volume":"18","author":"J Youhanna","year":"2024","unstructured":"Youhanna J, Tran V, Hyer R, Domnich A. Immunogenicity of enhanced influenza vaccines against mismatched influenza strains in older adults: a review of randomized controlled trials. Influenza Other Respir Viruses. 2024;18(4):e13286.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"1284_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","volume":"14","author":"JS Tregoning","year":"2018","unstructured":"Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccin Immunother. 2018;14(3):550\u201364.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"1284_CR23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cmi.2024.08.012","volume":"30","author":"H Bricout","year":"2024","unstructured":"Bricout H, Levant M-C, Assi N, Cr\u00e9pey P, Descamps A, Mari K, et al. The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021\u20132022 influenza season. Clin Microbiol Infect. 2024;30(12):1592\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1284_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","volume":"371","author":"CA DiazGranados","year":"2014","unstructured":"DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635\u201345.","journal-title":"N Engl J Med"},{"key":"1284_CR25","doi-asserted-by":"publisher","unstructured":"Johansen ND, Modin D, Loiacono MM, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. N Engl J Med. 2025;393(23):2291-2302. https:\/\/doi.org\/10.1056\/NEJMoa2509907.","DOI":"10.1056\/NEJMoa2509907"},{"key":"1284_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509834","author":"J Pardo-Seco","year":"2025","unstructured":"Pardo-Seco J, Rodr\u00edguez-Tenreiro-S\u00e1nchez C, Gin\u00e9-V\u00e1zquez I, Mallah N, Mir\u00e1s-Carballal S, Pi\u00f1eiro-Sotelo M, et al. High-dose influenza vaccine to reduce hospitalizations. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2509834.","journal-title":"N Engl J Med"},{"key":"1284_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijid.2022.10.041","volume":"125","author":"A Domnich","year":"2022","unstructured":"Domnich A, Panatto D, Pariani E, Napoli C, Chironna M, Manini I, et al. Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults. Int J Infect Dis. 2022;125:164\u20139.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"1284_CR28","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1111\/jgs.19176","volume":"72","author":"JM Ferdinands","year":"2024","unstructured":"Ferdinands JM, Blanton LH, Alyanak E, Chung JR, Trujillo L, Taliano J, et al. Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: a systematic review and network meta-analysis. J Am Geriatr Soc. 2024;72(12):3875\u201389.","journal-title":"J Am Geriatr Soc"},{"key":"1284_CR29","unstructured":"Centers for Disease Control and Prevention. Flu burden prevented by vaccination: 2023\u20132024 flu season. U.S. Department of Health & Human Services; 2025. https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis-vac\/2023-2024-prevented.html. Last Accessed 30 Oct 2025."},{"key":"1284_CR30","unstructured":"WHO. Vaccines against influenza: WHO position paper\u2014May 2022. 2022. https:\/\/www.who.int\/publications\/i\/item\/who-wer9719. Accessed 30 Oct 2025."},{"key":"1284_CR31","unstructured":"European Centre for Disease Prevention and Control. COVID-19 vaccination coverage in the EU\/EEA during the 2024\u201325 season campaigns 2025. 13 June 2025. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/covid-19-vaccination-coverage-eueea-during-2024-25-season-campaigns. Accessed 30 Oct 2025."},{"issue":"5","key":"1284_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/s41591-023-02282-y","volume":"29","author":"TA Stamm","year":"2023","unstructured":"Stamm TA, Partheym\u00fcller J, Mosor E, Ritschl V, Kritzinger S, Alunno A, et al. Determinants of COVID-19 vaccine fatigue. Nat Med. 2023;29(5):1164\u201371.","journal-title":"Nat Med"},{"key":"1284_CR33","unstructured":"European Centre for Disease Prevention and Control. Effective communication around the benefit and risk balance of vaccination in the EU\/EEA. 2024 May 2024. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/effective-communication-around-benefit-and-risk-balance-vaccination-eueea. Accessed 30 Oct 2025."},{"issue":"15","key":"1284_CR34","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323.","journal-title":"N Engl J Med"},{"key":"1284_CR35","doi-asserted-by":"publisher","unstructured":"Link-Gelles R, Chickery S, Webber A, et al. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged \u226518 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(6):73-82. https:\/\/doi.org\/10.15585\/mmwr.mm7406a1.","DOI":"10.15585\/mmwr.mm7406a1"},{"key":"1284_CR36","unstructured":"WHO. Considerations for pneumococcal vaccination in older adults. 2021. https:\/\/www.who.int\/publications\/i\/item\/WER9623-217-228. Accessed 30 Oct 2025."},{"key":"1284_CR37","unstructured":"Coalition for Life Course Immunisation. Pneumococcal Vaccination Atlas 2023. https:\/\/pneumoniaatlas.org\/. Last Accessed 30 Oct 2025."},{"key":"1284_CR38","unstructured":"(BCFI) BCvFI. Commented Medicines Repertoire 2025. https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=8902942&view=pvt&vmp_group=46078. Last Accessed 30 Oct 2025."},{"issue":"1","key":"1284_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2469424","volume":"21","author":"H Maeda","year":"2025","unstructured":"Maeda H, Morimoto K. Global distribution and characteristics of pneumococcal serotypes in adults. Hum Vaccin Immunother. 2025;21(1):2469424.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1284_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518\u00a0years. Clin Infect Dis. 2022;75(3):390\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1284_CR41","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/cid\/ciae383","volume":"79","author":"P Scott","year":"2024","unstructured":"Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, et al. A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (STRIDE-6). Clin Infect Dis. 2024;79(6):1366\u201374.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1284_CR42","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","volume":"24","author":"HL Platt","year":"2024","unstructured":"Platt HL, Bruno C, Buntinx E, Pelayo E, Garcia-Huidobro D, Barranco-Santana EA, et al. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. Lancet Infect Dis. 2024;24(10):1141\u201350.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1284_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s40267-024-01126-0","volume":"41","author":"S Duque","year":"2025","unstructured":"Duque S, Marinho A, Almeida P, Marques Pereira R, Buzaco R. Expanding the coverage of herpes zoster vaccination recommendations in European countries: the example of Portugal. Drugs Therapy Perspect. 2025;41(1):34\u201343.","journal-title":"Drugs Therapy Perspect"},{"key":"1284_CR44","unstructured":"WHO. WHO position paper on herpes zoster vaccines. Weekly Epidemiological Record. 100; 2025. https:\/\/www.who.int\/publications\/i\/item\/WER10027-28-265-284. Last Accessed 30 Oct 2025."},{"key":"1284_CR45","unstructured":"WHO. Market information for access (MI4A) 2024. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/vaccine-access\/mi4a. Accessed 30 Oct 2025."},{"key":"1284_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103241","author":"A Strezova","year":"2025","unstructured":"Strezova A, D\u00edez Domingo J, Cunningham AL, Eto T, Andrews C, Arns C, et al. Final analysis of the ZOE-LTFU trial to 11\u00a0years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. eClinMed. 2025. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103241.","journal-title":"eClinMed"},{"key":"1284_CR47","unstructured":"Superior Health Council. Vaccination against RSV for older adults. Brussels; 2024."},{"key":"1284_CR48","unstructured":"Bundesministerium f\u00fcr Arbeit S, Gesundheit, Pflege und Konsumentenschutz. Vaccination plan Austria 2025. https:\/\/www.sozialministerium.gv.at\/Themen\/Gesundheit\/Impfen\/Impfplan-%c3%96sterreich.html. Last Accessed 30 Oct 2025."},{"key":"1284_CR49","unstructured":"(BCFI) BCvFI. Vaccin tegen respiratoir syncytieel virus (RSV) 2025. https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=8904013. Last Accessed 30 Oct 2025."},{"key":"1284_CR50","unstructured":"GSK. European Commission approves expanded age indication for GSK\u2019s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50\u201359 at increased risk London: GSK; 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/european-commission-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk\/. Last Accessed 30 Oct 2025."},{"key":"1284_CR51","unstructured":"EMA. Abrysvo (Respiratory syncytial virus vaccine [bivalent, recombinant]) Amsterdam: European Medicines Agency; 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo. Last Accessed 30 Oct 2025."},{"key":"1284_CR52","unstructured":"EMA. Abrysvo: summary of product characteristics. EMA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abrysvo-epar-product-information_en.pdf. Last Accessed 30 Oct 2025."},{"key":"1284_CR53","unstructured":"EMA. Opinion on variation to marketing authorisation Amsterdam 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/mresvia. Last Accessed 30 Oct 2025."},{"key":"1284_CR54","doi-asserted-by":"crossref","unstructured":"Ison MG, Papi A, Langley JM, Lee D-G, Leroux-Roels I, Martinon-Torres F, et al., editors. 1936. Efficacy of one dose of the respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in adults \u2265\u00a060\u00a0years of age persists for 2 RSV seasons. Open Forum Infectious Diseases. Oxford: Oxford University Press US; 2023.","DOI":"10.1093\/ofid\/ofad500.2467"},{"issue":"24","key":"1284_CR55","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233\u201344.","journal-title":"N Engl J Med"},{"key":"1284_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf061","author":"EE Walsh","year":"2025","unstructured":"Walsh EE, Eiras D, Woodside J, Jiang Q, Patton M, Marc GP, et al. Efficacy, immunogenicity, and safety of the bivalent respiratory syncytial virus (RSV) prefusion F vaccine in older adults over 2 RSV seasons. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf061.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1284_CR57","doi-asserted-by":"publisher","first-page":"e2450832","DOI":"10.1001\/jamanetworkopen.2024.50832","volume":"7","author":"SY Tartof","year":"2024","unstructured":"Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, et al. Estimated vaccine effectiveness for respiratory syncytial virus\u2013related lower respiratory tract disease. JAMA Netw Open. 2024;7(12):e2450832-e.","journal-title":"JAMA Netw Open"},{"key":"1284_CR58","unstructured":"Surie D. Effectiveness of adult respiratory syncytial virus (RSV) vaccines, 2023\u20132024. 2024 June 26;2024."},{"issue":"1","key":"1284_CR59","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/infdis\/jiad546","volume":"230","author":"TF Schwarz","year":"2023","unstructured":"Schwarz TF, Hwang S-J, Ylisastigui P, Liu C-S, Takazawa K, Yono M, et al. Immunogenicity and safety following 1 dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial. J Infect Dis. 2023;230(1):e102\u201310.","journal-title":"J Infect Dis"},{"key":"#cr-split#-1284_CR60.1","unstructured":"Priddy F. RSV Vaccine (mRNA-1345) Update:- safety and immunogenicity in 18-59\u00a0year olds at increased risk for RSV disease revaccination of adults at 12 or 24\u00a0months ACIP presentation slides: 15-16 April, 2025 Meeting: Centers for Disease Control and Prevention"},{"key":"#cr-split#-1284_CR60.2","unstructured":"2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/02-Priddy-Adult-RSV-508.pdf. Last Accessed 30 Oct 2025."},{"issue":"4","key":"1284_CR61","doi-asserted-by":"publisher","first-page":"e905","DOI":"10.1093\/infdis\/jiae185","volume":"230","author":"EE Walsh","year":"2024","unstructured":"Walsh EE, Falsey AR, Zareba AM, Jiang Q, Gurtman A, Radley D, et al. Respiratory syncytial virus prefusion F vaccination: antibody persistence and revaccination. J Infect Dis. 2024;230(4):e905\u201316.","journal-title":"J Infect Dis"},{"key":"1284_CR62","unstructured":"WHO. Pertussis vaccines: WHO position paper\u2014August 2015. 2015."},{"issue":"1","key":"1284_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40520-021-02018-3","volume":"34","author":"JH Choi","year":"2022","unstructured":"Choi JH, de Correia Sousa J, Fletcher M, Gabutti G, Harrington L, Holden M, et al. Improving vaccination rates in older adults and at-risk groups: focus on pertussis. Aging Clin Exp Res. 2022;34(1):1\u20138.","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"1284_CR64","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cid\/cis627","volume":"55","author":"BC Liu","year":"2012","unstructured":"Liu BC, McIntyre P, Kaldor JM, Quinn HE, Ridda I, Banks E. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis. 2012;55(11):1450\u20136.","journal-title":"Clin Infect Dis"},{"key":"1284_CR65","volume":"61","author":"JU Jensen","year":"2025","unstructured":"Jensen JU, Johansen ND, Mathioudakis AG, Biering-S\u00f8rensen T, Sivapalan P. The silent exclusion: rethinking eligibility and generalizability in clinical trials. Lancet Reg Health. 2025;61:101605.","journal-title":"Lancet Reg Health"},{"issue":"2","key":"1284_CR66","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200206","volume":"2","author":"ND Johansen","year":"2023","unstructured":"Johansen ND, Modin D, Nealon J, Samson S, Salamand C, Loiacono MM, et al. A pragmatic randomized feasibility trial of influenza vaccines. NEJM Evid. 2023;2(2):EVIDoa2200206.","journal-title":"NEJM Evid"},{"issue":"5","key":"1284_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeaf102","volume":"5","author":"C Espersen","year":"2025","unstructured":"Espersen C, Johansen ND, Modin D, Janstrup KH, Loiacono MM, Harris RC, et al. Relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against clinical outcomes according to history of atrial fibrillation: a pre-specified analysis of the DANFLU-1 randomized trial. Eur Heart J Open. 2025;5(5):oeaf102.","journal-title":"Eur Heart J Open"},{"key":"1284_CR68","unstructured":"Biering-S\u00f8rensen T. A pragmatic randomized trial to evaluate the effectiveness of high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in older adults (DANFLU-2). Clinical Trials.be; 2022. https:\/\/clinicaltrial.be\/nl\/details\/23844?only_eligible=0&only_recruiting=0&per_page=100. Last Accessed 30 Oct 2025."},{"key":"1284_CR69","unstructured":"Biering-S\u00f8rensen T. Vaccine effectiveness of a bivalent RSV prefusion F protein-based vaccine for preventing RSV hospitalizations in older adults 2024. https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT06684743\/vaccine-effectiveness-of-a-bivalent-rsv-prefusion-f-protein-based-vaccine-for-preventing-rsv-hospitalizations-in-older-adults?country=Denmark&city=Holbuk. Last Accessed 30 Octo 2025."},{"key":"1284_CR70","doi-asserted-by":"crossref","unstructured":"Lassen MCH, Johansen ND, Christensen SH, et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. N Engl J Med. 2026;394(2):138-151. doi:10.1056\/NEJMoa2509810","DOI":"10.1056\/NEJMoa2509810"},{"issue":"22","key":"1284_CR71","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.2024.21060","volume":"332","author":"ND Johansen","year":"2024","unstructured":"Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Chatur S, Claggett BL, et al. Electronic nudges to increase influenza vaccination in patients with chronic diseases: a randomized clinical trial. JAMA. 2024;332(22):1900\u201311.","journal-title":"JAMA"},{"issue":"1","key":"1284_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","volume":"71","author":"LA Grohskopf","year":"2022","unstructured":"Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022-23 Influenza Season. MMWR Recomm Rep. 2022;71(1):1\u201328.","journal-title":"MMWR Recomm Rep"},{"issue":"8","key":"1284_CR73","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/infdis\/jiy716","volume":"220","author":"HS Izurieta","year":"2019","unstructured":"Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017\u20132018. J Infect Dis. 2019;220(8):1255\u201364.","journal-title":"J Infect Dis"},{"key":"1284_CR74","unstructured":"EMA. Real-world evidence framework to support EU regulatory decision-making. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/report\/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained-regulator-led-studies-september-2021-february-2023_en.pdf. Accessed 30 Oct 2025."},{"issue":"1","key":"1284_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1284_CR76","unstructured":"El Banhawi H, Chowdhury S, Neri M, Radu P, Besley S, Bell E, Brassel S, Steuten L. The socioeconomic value of adult immunisation programmes. OHE Contract Research Report: Office of Health Economics. https:\/\/www.ohe.org\/publications\/the-socio-economic-value-of-adult-immunisation-programmes\/. Last Accessed 30 Oct 2025; 2024."},{"issue":"1","key":"1284_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahr.2023.100176","volume":"4","author":"HR Fuller","year":"2024","unstructured":"Fuller HR, Huseth-Zosel A, Van Vleet B, Carson PJ. Barriers to vaccination among older adults: demographic variation and links to vaccine acceptance. Aging Health Res. 2024;4(1):100176.","journal-title":"Aging Health Res"},{"issue":"10","key":"1284_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101141","volume":"12","author":"M Lamot","year":"2024","unstructured":"Lamot M, Kirbi\u0161 A. Understanding vaccine hesitancy: a comparison of sociodemographic and socioeconomic predictors with health literacy dimensions. Vaccines. 2024;12(10):1141.","journal-title":"Vaccines"},{"key":"1284_CR79","doi-asserted-by":"crossref","unstructured":"Heinemeier D, Schmid P, Eitze S, Betsch C, Vaccination60+ study g. Influenza and pneumococcal vaccine hesitancy in the elderly population: results from two representative surveys in Germany. BMC Public Health. 2025;25(1):1672.","DOI":"10.1186\/s12889-025-22441-9"},{"key":"1284_CR80","unstructured":"CDC. Timing and spacing of immunobiologics 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-best-practices\/timing-spacing-immunobiologics.html. Last Accessed 30 Oct 2025."},{"key":"1284_CR81","unstructured":"WHO. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-coadministration-influenza-vaccines. Accessed 30 Oct 2025."},{"issue":"1","key":"1284_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2195786","volume":"19","author":"P Bonanni","year":"2023","unstructured":"Bonanni P, Steffen R, Schelling J, Balaisyte-Jazone L, Posiuniene I, Zato\u0144ski M, et al. Vaccine co-administration in adults: an effective way to improve vaccination coverage. Hum Vaccin Immunother. 2023;19(1):2195786. https:\/\/doi.org\/10.1080\/21645515.2023.2195786.","journal-title":"Hum Vaccin Immunother"},{"key":"1284_CR83","unstructured":"Immunize.org. 65+ FLU DEFENSE. https:\/\/www.influenza-defense.org\/. Last Accessed 30 Oct 2025."},{"issue":"1","key":"1284_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2390227","volume":"20","author":"A Addario","year":"2024","unstructured":"Addario A, Pardo M, Gavazzi G, et al. The desire of autonomy: a lever for vaccination of the elderly? Results of a qualitative study. Hum Vaccin Immunother. 2024;20(1):2390227. https:\/\/doi.org\/10.1080\/21645515.2024.2390227.","journal-title":"Hum Vaccin Immunother"},{"key":"1284_CR85","unstructured":"European Centre for Disease Prevention and Control. Pertussis: Recommended vaccinations 2024. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=3&SelectedCountryIdByDisease=-1. Accessed 30 Oct 2025."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01284-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:02:40Z","timestamp":1773802960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01284-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.D.R. reports having collaborated on research projects related to the epidemiology of influenza, RSV, and SARS-CoV-2, funded by, or having provided consultancy services to, or received research or travel grants from, AstraZeneca, GSK, CSL Seqirus, Moderna, MSD, Pfizer, and Sanofi. S.M. has been an advisory board member\/conference speaker\/researcher and\/or received educational grants from Sanofi, GSK, Pfizer, Moderna, Viatris, and Merck. M.C. has received advisory board, consulting\/advisory, and lecture honoraria from: AbbVie, Abbott, Alexion, Amgen, Angelini, Astellas, Astra Zeneca, Boehringer Ingelheim, Biogen, BMS, Eli Lilly, GSK, Janssen, Krka, Medison, MSD, Novartis, Novo Nordisk, Pfizer, Pro.med, Roche, Sandoz, Sanofi, Servier, Takeda, Teva, UCB, and Vertex. J.P.M. reports consultancy services for Pfizer. The other authors report no other interests. Vaccines Europe provides an unrestricted grant to support the activities and meetings of the Adult Immunization Board (AIB). However, it\u2019s important to note that the secretariat of the AIB retains full control over meeting topics, meeting reports, and content on the website. The AIB and its advisors place great importance on maintaining strict operational and scientific independence. The secretariat operates in full compliance with the ethical guidelines of the Universities of Antwerp and Florence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Supported by Katherine Newell (AIB medical writer). All authors contributed to the conception, drafting, and critical revision of the manuscript and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}